Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stupp, R.
Right arrow Articles by Baumert, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stupp, R.
Right arrow Articles by Baumert, B. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1695-1696, 2003
© 2003 European Society for Medical Oncology

Editorial

Promises and controversies in the management of low-grade glioma

R. Stupp1 and B. G. Baumert2

1 Multidisciplinary Oncology Center, University Hospital, Lausanne, Switzerland; 2 Department of Radiation-Oncology, University Hospital, Maastricht, The Netherlands (E-mail: b.baumert@rtil.nl or Roger.Stupp@chuv.hospvd.ch)

The first 10% of the full text of this article appears below.

Low-grade gliomas (LGGs) are a heterogeneous group of relatively slow-growing primary tumors of astrocytic and/or oligodendroglial origin. Peak incidence occurs in the second and third decade of life. Many patients will present with easily controlled seizures and will remain stable for many years, whereas others may progress rapidly, with increasing neurological symptoms, to a higher-grade tumor. Although morphologically indistinguishable at diagnosis, the time interval to progression varies considerably from a few months to several years. To date treatment options were limited to surgery when feasible, and radiotherapy and palliative chemotherapy at recurrence. Oligodendroglioma with specific molecular changes (allelic loss on chromosomes 1p and 19q) have been recognized over the last decade to be . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
R. Stupp, M. E. Hegi, M. R. Gilbert, and A. Chakravarti
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
J. Clin. Oncol., September 10, 2007; 25(26): 4127 - 4136.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist, February 1, 2006; 11(2): 165 - 180.
[Abstract] [Full Text] [PDF]